Protagonist Therapeutics (PTGX) Current Deferred Revenue (2017 - 2025)
Historic Current Deferred Revenue for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $14.2 million.
- Protagonist Therapeutics' Current Deferred Revenue fell 6077.35% to $14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year decrease of 6077.35%. This contributed to the annual value of $18.9 million for FY2024, which is 62960000.0% up from last year.
- Per Protagonist Therapeutics' latest filing, its Current Deferred Revenue stood at $14.2 million for Q3 2025, which was down 6077.35% from $14.7 million recorded in Q2 2025.
- In the past 5 years, Protagonist Therapeutics' Current Deferred Revenue ranged from a high of $45.0 million in Q1 2024 and a low of $3000.0 during Q3 2023
- Over the past 5 years, Protagonist Therapeutics' median Current Deferred Revenue value was $4.0 million (recorded in 2021), while the average stood at $12.5 million.
- Per our database at Business Quant, Protagonist Therapeutics' Current Deferred Revenue plummeted by 9857.21% in 2022 and then skyrocketed by 120656666.67% in 2024.
- Over the past 5 years, Protagonist Therapeutics' Current Deferred Revenue (Quarter) stood at $1.6 million in 2021, then plummeted by 95.69% to $69000.0 in 2022, then tumbled by 95.65% to $3000.0 in 2023, then surged by 629600.0% to $18.9 million in 2024, then decreased by 24.83% to $14.2 million in 2025.
- Its Current Deferred Revenue was $14.2 million in Q3 2025, compared to $14.7 million in Q2 2025 and $16.9 million in Q1 2025.